48th week of 2011 patent applcation highlights part 41 |
Patent application number | Title | Published |
20110293642 | Modulation of Splenocytes in Cell Therapy - The invention provides methods for treating pathological conditions associated with an undesirable inflammatory component. The invention is generally directed to reducing inflammation by administering cells that have one or more of the following effects in an injured subject: interact with splenocytes, preserve splenic mass, increase proliferation of CD4 | 2011-12-01 |
20110293643 | COMPOUNDS AND METHODS FOR INHIBITING MMP2 AND MMP9 - The present invention relates to specific inhibitors of MMP2 and MMP9 and their use in immunosuppression. | 2011-12-01 |
20110293644 | COMPOSITIONS AND METHODS FOR TREATMENT OF CELIAC DISEASE - The invention provides agents and vaccines for treating and diagnosing celiac disease. In particular, the present invention provides a combination of three peptides that are useful for treating and diagnosing celiac disease in a large proportion of patients. | 2011-12-01 |
20110293645 | WDRPUH EPITOPE PEPTIDES AND VACCINES CONTAINING THE SAME - The present invention provides peptides containing the amino acid sequence of SEQ ID NOs: 1, 2, 3, 4, 16, 17, 30, 31, 34, 36, 37, 40, 41, 45, 49, 55, 57 and 61, as well as peptides containing the above-mentioned amino acid sequences in which 1, 2, or several amino acid(s) are substituted, deleted, inserted or added, but still have cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing tumors, which drugs containing these peptides. The peptides of the present invention can also be used as vaccines. | 2011-12-01 |
20110293646 | PAN-DR Binding Polypeptides and Uses Thereof - The present invention provides novel artificial oligopeptides capable of binding HLA Class II molecules encoded by several alleles. The oligopeptides include the sequence AX | 2011-12-01 |
20110293647 | IMMUNOGENIC LHRH COMPOSITIONS AND METHODS RELATING THERETO - The present invention relates generally to an immunogenic LHRH composition and more particularly to an immunogenic LHRH composition comprising a LHRH C-terminal fragment of at least five amino acids. The present invention is useful, inter alia, as a prophylactic and/or therapeutic agent for the modification of fertility and behaviour patterns of animals, the achievement of livestock production gains such as increasing growth, decreasing feed conversion ratios or the control of unwanted organoleptic characteristics or the treatment of disorders of the reproductive organs. | 2011-12-01 |
20110293648 | SSX-2 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES - The invention describes HLA class II binding peptides encoded by the SSX-2 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating to the peptides. The peptides stimulate the activity and proliferation of CD4 | 2011-12-01 |
20110293649 | In Vivo Activation of Antigen Presenting Cells for Enhancement of Immune Responses Induced by Virus Like Particles - The invention relates to the finding that stimulation of antigen presenting cell (APC) activation using substances such as anti-CD40 antibodies or DNA oligomers rich in non-methylated C and G (CpGs) can dramatically enhance the specific T cell response obtained after vaccination with recombinant virus like particles (VLPs) coupled, fused or otherwise attached to antigens. While vaccination with recombinant VLPs fused to a cytotoxic T cell (CTL) epitope of lymphocytic choriomeningitis virus induced low levels cytolytic activity only and did not induce efficient anti-viral protection, VLPs injected together with anti-CD40 antibodies or CpGs induced strong CTL activity and full anti-viral protection. Thus, stimulation of APC-activation through antigen presenting cell activators such as anti-CD40 antibodies or CpGs can exhibit a potent adjuvant effect for vaccination with VLPs coupled, fused or attached otherwise to antigens. | 2011-12-01 |
20110293650 | INFLUENZA VIRUS-LIKE PARTICLES (VLPS) COMPRISING HEMAGGLUTININ - A method for synthesizing influenza virus-like particles (VLPs) within a plant or a portion of a plant is provided. The method involves expression of influenza HA of type A/California/04/09 in plants and the purification by size exclusion chromatography. The invention is also directed towards a VLP comprising influenza HA protein of type A/California/04/09 and plants lipids. The invention is also directed to a nucleic acid encoding influenza HA of type A/California/04/09 as well as vectors. The VLPs may be used to formulate influenza vaccines, or may be used to enrich existing vaccines. | 2011-12-01 |
20110293651 | HPV E6 protein T cell epitopes and uses thereof - The present invention is directed to the examination of the pattern of immunodominant T cell epitopes in the E6 protein of Human Papilloma virus and its further characterization in terms of its amino acid sequence and Human Leukocyte Antigen restriction. These epitopes are identified based on their ability to induce specific T cell responses and therefore, are important as sources of antigens for immunotherapies to treat cervical and other cancers. The present invention contemplates identifying a number of similar epitopes restricted by a wide variety of Human Leukocyte Antigen types so that they can be used together to develop preventative or therapeutic vaccines, which can be used for the general human population. The present invention also contemplates using E6 peptides of Human Papilloma virus as a diagnosis method to predict the probability of developing persistent cervical neoplasia in an individual. | 2011-12-01 |
20110293652 | CHIMERIC OSPA GENES, PROTEINS, AND METHODS OF USE THEREOF - The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of | 2011-12-01 |
20110293653 | ANTAGONISTS OF MIR-155 FOR THE TREATMENT OF INFLAMMATORY LIVER DISEASE - Provided herein are methods of treating or preventing an inflammatory liver disease in a subject, such as alcoholic liver disease (ALD), by administering to said subject an miR-155 antagonist. | 2011-12-01 |
20110293654 | SUBSTITUTED CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS - Substituted fused [1,2]imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a —CH(—R | 2011-12-01 |
20110293655 | Porcine Adenovirus 3-Based PRRSV Vaccines - The invention relates to a porcine adenovirus 3 based vaccine for the treatment of PRRS virus infection where the PADV3 is a recombinant replication competent PADV3 that comprises a nucleic acid that encodes a novel fusion protein of PRRSV ORF6 and a modified PRRSV ORF5 either alone or in combination with a PRRSV ORF. | 2011-12-01 |
20110293656 | RECOMBINANT MVA CAPABLE OF EXPRESSING STRUCTURAL HCV ANTIGENS - The invention relates to recombinant MVA which is capable of expressing structural HCV antigens, functional parts of said structural antigens or epitopes of said structural antigens. The invention further relates to a pharmaceutical composition, especially in the form of a vaccine and containing the recombinant MVA according to the invention, to eukaryotic cells that contain the inventive recombinant MVA and to various uses of the recombinant MVA, for example for producing recombinant structural proteins, for producing a pharmaceutical preparation that is suitable for the therapy and prophylaxis of HCV infections and diseases thereby caused. The invention further relates to methods for producing recombinant MVA and recombinant structural HCV polypeptides encoded by said recombinant MVA, and to DNA or RNA of said recombinant MVA. | 2011-12-01 |
20110293657 | ENCAPSULATED VACCINES FOR THE ORAL VACCINATION AND BOOSTERING OF FISH AND OTHER ANIMALS - The invention relates to a composition comprising a pharmaceutically active agent and a bioadhesive delivery system that provides for the oral delivery of a vaccine to animals, particularly aquatic animals. | 2011-12-01 |
20110293658 | USE OF INKT OR TLR AGONISTS FOR PROTECTING AGAINST OR TREATING A DISEASE SUCH AS ACUTE INFECTION OR CANCER - A method of protecting a mammalian subject against, or treating, a disease, wherein the mammalian subject has elevated numbers and/or activities of MDSC comprising administering to the subject a pharmaceutically acceptable amount of an iNKT agonist, such as alpha galactosylceramide or an analogue thereof, or a TLR agonist, or a combination thereof. | 2011-12-01 |
20110293659 | METHOD FOR THE ORAL/MUCOSAL VACCINATION BY MEANS OF RECOMBINANT YEASTS - Recombinant yeast cells are produced which are used for vaccination, among other uses for the oral vaccination by feeding. | 2011-12-01 |
20110293660 | NOVEL METHOD - The present invention relates to a method for purifying a virus, or a viral antigen thereof, comprising at least the following steps: a) obtaining a fluid comprising the virus, or a viral antigen thereof, and b) purifying the fluid by at least one density gradient ultracentrifugation step, wherein the ratio of the amount of virus, or viral antigen thereof, present in the fluid over the density gradient volume is less than 1, less than 0.8, less than 0.6 and less than 0.4. | 2011-12-01 |
20110293661 | VACCINE STRAINS OF BRACHYSPIRA HYODYSENTERIAE - The present invention relates generally to vaccine strains of | 2011-12-01 |
20110293662 | COMPOSITIONS COMPRISING REDUCED GENOME BACTERIA FOR USE IN TREATMENT OF SEPSIS - Methods for prophylaxis or treatment of sepsis in a subject are provided comprising administering to the subject a therapeutically effective dose of multiple deletion strain bacteria. | 2011-12-01 |
20110293663 | Pharmaceutical botulinum toxin compositions - Botulinum toxin, a well know systemic poison, produces favorable therapeutic effect by virtue of regionally attaching to nerves within the myoneural junction and possibly other tissues in a target region of a particular tissue. The present invention provides compositions of botulinum toxin and a sequestration agent that increase sequestration and delivery of the botulinum toxin to neural and associated tissues, as compared with available formulations of botulinum toxins, and thereby produce a beneficial clinical effect. The sequestration agents of the present invention include proteins, lipids and carbohydrates. A preferred composition of the present invention comprises a botulinum toxin and an albumin. The present invention also provides methods of treating neuromuscular diseases and pain using the disclosed compositions and methods of making the disclosed compositions. | 2011-12-01 |
20110293664 | CHLAMYDIA ANTIGENS AND USES THEREOF - Disclosed are novel chlamydia antigens, nucleic acids encoding the antigens, and immunogenic compositions including the antigens. Methods of using the antigens to elicit immune responses (e.g., T cell-mediated and/or B cell-mediated immune responses) comprising administering an immunogenic composition including one or more of the novel antigens may be used for prophylaxis and/or treatment of chlamydia-mediated diseases. | 2011-12-01 |
20110293665 | Recombinant Der P 2 Expressed in Pichia Pastoris as a "Natural-Like" Allergen for Immunotherapy and Diagnostic Purposes - The present invention concerns a method for producing a recombinant | 2011-12-01 |
20110293666 | Bioengineered Tissue Constructs and Methods for Production and Use - Bioengineered constructs are formed from cultured cells induced to synthesize and secrete endogenously produced extracellular matrix components, e.g., without the requirement of exogenous matrix components or network support or scaffold members. The bioengineered constructs of the invention can be treated in various ways such that the cells of the bioengineered constructs can be devitalized and/or removed without compromising the structural integrity of the constructs. Moreover, the bioengineered constructs of the invention can be used in conjunction with biocompatible/bioremodelable solutions that allow for various geometric configurations of the constructs. | 2011-12-01 |
20110293667 | Bioengineered Tissue Constructs and Methods for Producing and Using Thereof - Bioengineered constructs are formed from cultured cells induced to synthesize and secrete endogenously produced extracellular matrix components without the requirement of exogenous matrix components or network support or scaffold members. The bioengineered constructs of the invention can be produced with multiple cell types that can all contribute to producing the extracellular matrix. Additionally or alternatively, one of the multiple cell types can be delivered to a site in the body via the endogenously produced extracellular matrix components to achieve various therapeutic benefits. | 2011-12-01 |
20110293668 | ORAL ODOR CONTROL METHOD AND PRODUCT - A product and method for controlling mouth odor and bad breath using an oral care product containing an odor neutralizer. The product for use in oral care or for use in the mouth to control mouth odors includes an odor neutralizer compound. In a preferred method of manufacture, the O.M. Complex oral compound is mixed into a concentrated flavor material. The concentrated flavor material is then added in small percentages to the product during manufacture so that the resulting product includes the odor neutralizer compound. The product may be used in the ordinary manner by a user and during use the O.M. Complex oral compound serves to capture and neutralize odor causing compounds. | 2011-12-01 |
20110293669 | HYDROGEL IMPLANTS WITH VARYING DEGREES OF CROSSLINKING - The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with both denser and less dense regions. | 2011-12-01 |
20110293670 | ADHESIVE MATERIAL CONTAINING 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE - There is provided an adhesive preparation containing 5-methyl-1-phenyl-2-(1H)-pyridone. The adhesive preparation is a 5-methyl-1-phenyl-2-(1H)-pyridone-containing adhesive preparation including an active medicinal ingredient-containing layer, characterized in that the active medicinal ingredient-containing layer contains an lipophilic base, a dissolving agent (except glycerin and a medium-chain aliphatic acid triglyceride), and 5-methyl-1-phenyl-2-(1H)-pyridone or medically acceptable salts thereof. | 2011-12-01 |
20110293671 | BACTERIOPHAGE COMPOSITIONS FOR TREATMENT OF BACTERIAL INFECTIONS - A respirable composition for treatment of a bacterial infection includes one or more active bacteriophages in combination with a pharmaceutically acceptable respirable carrier. The composition includes a carbohydrate carrier, and is prepared as fine powder. In another aspect, bacteriophages are provided in a liquid carrier for administration by nebulization. In one aspect, the bacteriophages have anti-bacterial activity against one or more species or strains of | 2011-12-01 |
20110293672 | PANCREATIC TUMOUR TREATMENT - There is provided a composition comprising microspheres which comprise a water-insoluble, water-swellable polymer and associated with the polymer, in releasable form, a chemotherapeutic agent, for use in the treatment of a pancreatic tumour or cyst, wherein the microspheres, when equilibrated in water at 37° C., comprise at least 40 wt % water based on weight of polymer plus water, wherein the polymer is anionically charged at pH7 and the chemotherapeutic agent is cationically charged and electrostatically associated with the polymer. Also provided are methods of treating pancreatic tumours or cysts using this composition. | 2011-12-01 |
20110293673 | ORAL FILM-FORM BASE AND ORAL FILM-FORM PREPARATION - The present invention provides a film-form base having one or more sugars or sugar alcohols dispersed as fine particles therein, and also provides a film-form preparation containing the base and a drug. The base is produced by dispersing, in an organic solvent having a solubility parameter of 9.7 or higher, an edible polymer soluble in water and the organic solvent, and particles of one or two or more compounds selected from the group consisting of mono- to hexasaccharide sugars and sugar alcohols thereof which have an average particle size of 0.1 μm to 60 μm and are insoluble in an organic solvent. The present invention can therefore provide oral film-form base and preparation which have a rapid dissolution profile in the mouth and sufficient film strength, and provide a reduced sticky sensation attributed to the water-soluble polymer in the mouth and an improved feel when handled with the fingers. | 2011-12-01 |
20110293674 | MICRO-RNAs THAT MODULATE SMOOTH MUSCLE PROLIFERATION AND DIFFERENTIATION - The present invention relates to the identification of microRNAs that regulate smooth muscle cell proliferation and differentiation, including the miR-143/miR-145 cluster. Methods of treating restenosis and neointima formation by increasing expression of miR-143 and/or miR-145 are disclosed. The present invention also relates to the identification of two microRNAs, miR-486 and miR-422a, that regulate cell survival in the heart. Methods of treating or preventing cardiac hypertrophy, heart failure, or myocardial infarction by increasing expression of miR-486 and/or miR-422a in heart tissue are also disclosed. | 2011-12-01 |
20110293675 | COATINGS OF ACRYLAMIDE-BASED COPOLYMERS - An implantable device including conjugate formed of an acrylamide-based copolymer and a bioactive agent is provided. | 2011-12-01 |
20110293676 | Oral Cephalotaxine Dosage Forms - The present disclosure provides oral dosage forms comprising a cephalotaxine and a pharmaceutically acceptable carrier selected from protein, carbohydrate and lipid, an oral dosage form comprising cephalotaxine and a second active agent, as well as methods of treating subjects with such oral formulations. | 2011-12-01 |
20110293677 | Fabric And Fibre Conditioning Additives - A fabric, fibre, hair or skin conditioning additive for use in a liquid cleaning product is encapsulated within a shell comprising a silicon-containing polymer network. | 2011-12-01 |
20110293678 | Micellarly integrated oxidation protection for natural dyes - In order to formulate natural dyes, which are insoluble or sparingly soluble in water, in such a way that the dye is protected against oxidation, also and in particular after being incorporated into the end product with dilution, and which as a replacement for azo dyes in a beverage result in a solution which is clear to the human eye, the invention provides a solubilizate and a method for preparing a solubilizate. The solubilizate contains at least one natural dye that is insoluble or sparingly soluble in water, at least one emulsifier having an HLB value of 8 to 19, and at least two antioxidants. The dye and the antioxidants are present enclosed together in micelles. | 2011-12-01 |
20110293679 | METHOD FOR COATING MICROSPHERES ONTO A FLEXIBLE MATERIAL - The invention relates to a method for coating polymer microspheres laden with one or more active substances onto a flexible material without melting, comprising the following steps: a) selecting a porous crosslinked polymer; b) incorporating a liquid lipophilic composition at room temperature and containing at least one active substance into the polymer by heating at a temperature higher by 1 to 5° C. than the glass transition temperature of the polymer in order to obtain laden microspheres; c) placing the laden microspheres on the flexible material; d) heating the flexible material with the laden microspheres at a temperature higher by 1 to 10° C. than the polymer melting temperature; e) cooling the flexible material impregnated with the laden microspheres. The coated flexible material of the invention is laden with one or more active substances having a therapeutic, dermatological cosmetic or olfactory effect and the diffusion is controlled on the basis of the polymers used for making the microspheres and on the nature of the active substances. | 2011-12-01 |
20110293680 | Composition of a Temporary Hair Thickener - The present invention relates to a composition of a temporary hair thickener. In particular, the present invention relates to a composition of a temporary hair thickener comprising bamboo charcoal powder, a hydrophobic waterproof coating agent, a low grade alcohol and a propellant in a specific amount. The composition of a temporary hair thickener in accordance with the present invention can be attached to hair for a longer time as compared with the prior art hair thickeners, thereby showing improved persistency. Further, since the thickener ingredients of the composition are hardly flowed down or detached from hairs by rain or sweat, the composition of the present invention solves the problem of blotting the skin and clothes. | 2011-12-01 |
20110293681 | HAND SANITIZING PATCH HAVING AN INTEGRALLY BONDED ANTIMICROBIAL - The present invention provides for topical adhesive patch that includes a backing having a front side and a back side; a formulation in contact with the front side of the backing, the formulation including an adhesive; and at least one antimicrobial. The antimicrobial is integrally bonded to the back side of the backing. The present invention also provides for a method of reducing the number of microbes located upon a topical skin surface of a mammal, as well as a method of preventing the transmission of a communicable disease capable of being transmitted by physical contact. The methods include topically contacting a skin surface of the mammal with the back side of the topical adhesive patch. | 2011-12-01 |
20110293682 | SELF-TRIGGERED MICROENCAPSULATED BIOCIDES AND/OR FUNGICIDES - One embodiment includes a biocide-containing and/or fungicide-containing microcapsule wherein the microcapsule may be capable of degradation due to the presence of byproducts that are released by a fungi or biological organism. Upon release, the biocide and/or fungicide may then be utilized to eliminate the fungi or biological organism. | 2011-12-01 |
20110293683 | Silver antimicrobial composition with extended shelf-life - A method for extending the shelf-life of an aqueous dispersion comprising silver halide particles and gelatin, comprises adding adenine to the aqueous dispersion in an amount effective to improve the redispersibility and the colloidal stability thereafter of the aqueous dispersion following extended storage. The extended storage time consisted of 5 days at a temperature of about 40° C. The gelatin amount ranged from about 4 weight % to less than about 1 weight %. The invention also relates to a method of coating fibers, fabrics or substrates with the improved composition to provide antimicrobial properties, and to the coated articles. | 2011-12-01 |
20110293684 | SURFACE-COATED STRUCTURES AND METHODS - The present invention relates to a methods and composition in which a D-form or retro-inverso | 2011-12-01 |
20110293685 | SCAFFOLDS FOR TISSUE ENGINEERING AND REGENERATIVE MEDICINE - The methods and compositions described herein relate to novel 3-dimensional porous scaffolds useful for tissue re-generation, enhancement, or tissue repair. Electrospinning or other methods are used to create mats comprised of fibers that can be seeded with cells and subsequently rolled into a desired shape/form to replace a desired tissue. | 2011-12-01 |
20110293686 | Anti-viral compositions and methods for administration - Certain embodiments disclosed relate to compositions, including therapeutic compositions, methods, articles of manufacture, systems, and devices. Certain embodiments relate to anti-viral compositions, methods, articles of manufacture, systems and devices. | 2011-12-01 |
20110293687 | HYDROGEL IMPLANTS WITH VARYING DEGREES OF CROSSLINKING - The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with both denser and less dense regions. | 2011-12-01 |
20110293688 | HYDROGEL IMPLANTS WITH VARYING DEGREES OF CROSSLINKING - The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with both denser and less dense regions. | 2011-12-01 |
20110293689 | IMMOBILIZED BIOLOGICALLY ACTIVE ENTITIES HAVING A HIGH DEGREE OF BIOLOGICAL ACTIVITY - The present invention relates to immobilized biologically active entities having heparin cofactor II binding activity. | 2011-12-01 |
20110293690 | Biodegradable Polymer Encapsulated Microsphere Particulate Film and Method of Making Thereof - Films containing microsphere particles and processes for forming thereof are disclosed. The microsphere particles encapsulate one or more bioactive agents and may be deposited on a surface of medical devices or be used to form a medical device. | 2011-12-01 |
20110293691 | MULTIMODAL ADHESION BARRIER - Provided herein are multimodal barrier materials useful for preventing adhesions in a subject, which may include a collagen, a collagen deposition inhibitor and/or a chitosan. | 2011-12-01 |
20110293692 | HYDROGEL IMPLANTS WITH VARYING DEGREES OF CROSSLINKING - The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with both denser and less dense regions. | 2011-12-01 |
20110293693 | QUANTUM UNIT OF INHERITANCE VECTOR THERAPY - The innovative treatment strategy described here utilizes configurable microscopic medical payload delivery devices to act as a transport vector to deliver quantum genes to specific type of cells in the body. Utilizing probes on the exterior of the transport device, transport device locate specific target cell types in the body. Once a specific target cell type has been encountered, the configurable microscopic medical payload delivery device inserts its payload of quantum genes into the target cell type. By delivering quantum genes to specific type of cells, genes can be activated or inactivated in those specific type of cells. These medically therapeutic quantum genes are intended to improve cell function or the longevity of cells or neutralize harmful cells that pose a hazard to the general health of the body. | 2011-12-01 |
20110293694 | QUANTUM UNIT OF INHERITANCE VECTOR THERAPY METHOD - The innovative treatment method described here utilizes configurable microscopic medical payload delivery devices to act as a transport vector to deliver quantum genes to specific type of cells in the body. Utilizing probes on the exterior of the transport device, transport device locate specific target cell types in the body. Once a specific target cell type has been encountered, the configurable microscopic medical payload delivery device inserts its payload of quantum genes into the target cell type. By delivering quantum genes to specific type of cells, genes can be activated or inactivated in those specific type of cells. This method of delivering medically therapeutic quantum genes to specific cells is intended to improve cell function or extend the longevity of cells or neutralize harmful cells that pose a hazard to the body. | 2011-12-01 |
20110293695 | Amphoteric liposomes - Amphoteric liposomes are proposed, which comprise positive and negative membrane-based or membrane-forming charge carriers as well as the use of these liposomes. | 2011-12-01 |
20110293696 | COMPOSITIONS AND METHODS FOR TREATING BRUISES - A composition for the treatment of bruising is disclosed. The composition can include an antioxidant, one or more citrus flavanoids, as active agents along with a pharmaceutically acceptable excipient or filler. The compositions are nutriceutical formulations having the capacity to reduce the number of bruises that occur over time and that reduce the healing time of bruises. The compositions are preferably in tablet form for oral consumption one or more times per day. A method of reducing bruising is also disclosed in which a patient in need of a treatment for bruising or at risk of developing bruises is identified. The composition can then be administered orally to the patient. | 2011-12-01 |
20110293697 | HIV-1 Immunogenic Compositions - The present invention encompasses vaccine and/or immunogenic compositions against HIV and their methods of use for the prevention and/or treatment of HIV infection and/or AIDS. The vaccine and/or immunogenic compositions may contain an isolated HIV protein or fragment thereof, an adjuvant comprising a Toll like receptor (TLR) 4 ligand, in combination with a saponin. | 2011-12-01 |
20110293698 | Reagents and Methods for Treating Cancer - This invention describes a genetic system for targeting the EVI1 gene in mammalian cells. The EVI1 gene is an oncogenic transcription factor that, when expressed, accelerates cell division and inhibits death of cells. Nucleotide sequences that block the expression of EVI1 and drug delivery systems for them are described. These nucleotide sequences cause a block in cell growth and division and trigger death of mammalian cells, including lung and ovarian cancer cells. | 2011-12-01 |
20110293699 | HYDROGEL IMPLANTS WITH VARYING DEGREES OF CROSSLINKING - The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with both denser and less dense regions. | 2011-12-01 |
20110293700 | NANOCARRIER COMPOSITIONS WITH UNCOUPLED ADJUVANT - Disclosed are synthetic nanocarrier compositions with separate adjuvant compositions as well as related methods. | 2011-12-01 |
20110293701 | MULTIVALENT SYNTHETIC NANOCARRIER VACCINES - The invention relates, at least in part, to compositions comprising populations of synthetic nanocarriers that comprise different sets of antigens as well as related methods. | 2011-12-01 |
20110293702 | Compounds and Methods for the Treatment of Inflammatory Diseases of the CNS - Inflammatory diseases in the CNS can be treated or alleviated by the administration of an oligonucleotide in an amount sufficient to reduce the influx of mononuclear cells to the central nervous system by down-regulating the expression of at least one cell surface marker. For example multiple sclerosis can be treated or at least alleviated, by the administration of an oligonucleotide in a dose effective to inhibit or reduce the influx of mononuclear and/or autoaggressive cells to the central nervous system. The oligonucleotide can be used alone, or in combination with other treatment strategies. | 2011-12-01 |
20110293703 | AMINOALCOHOL LIPIDOIDS AND USES THEREOF - Aminoalcohol lipidoids are prepared by reacting an amine with an epoxide-terminated compound are described. Methods of preparing aminoalcohol lipidoids from commercially available starting materials are also provided. Aminoalcohol lipidoids may be prepared from racemic or stereochemically pure epoxides. Aminoalcohol lipidoids or salts forms thereof are preferably biodegradable and biocompatible and may be used in a variety of drug delivery systems. Given the amino moiety of these aminoalcohol lipidoid compounds, they are particularly suited for the delivery of polynucleotides. Complexes, micelles, liposomes or particles containing the inventive lipidoids and polynucleotide have been prepared. The inventive lipidoids may also be used in preparing microparticles for drug delivery. They are particularly useful in delivering labile agents given their ability to buffer the pH of their surroundings. | 2011-12-01 |
20110293704 | PRIMING OF AN IMMUNE RESPONSE - The present invention relates to a technology and method of priming of an immune response using invariant chain linked antigen, when these are used to prime a subsequent booster immunization using any suitable vacci. | 2011-12-01 |
20110293705 | METHODS AND COMPOSITIONS FOR LOCALIZED AGENT DELIVERY - The invention provides compositions and methods for delivering agents to localized regions, tissues, or organs in vivo by conjugating agent-loaded nanoparticles to cells having homing capability. The agents may be therapeutic or diagnostic agents such as cancer chemotherapeutic agents and imaging agents respectively. | 2011-12-01 |
20110293706 | NANOSHELLS ON POLYMERS - Nano-constructscomprising nanoshells and methods of using the nano-constructs for treating or ameliorating a medical condition are provided. | 2011-12-01 |
20110293707 | USE OF THE CATHELICIDIN LL-37 AND DERIVATIVES THEREOF FOR WOUND HEALING - Use of the antimicrobial cathelicidin peptide II-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of epithelial and stromal cells and thereby healing of wounds, such as chronic ulcers. The cytotoxic effect of LL-37 may be reduced by including a bilayer-forming polar lipid, especially a digalactosyldiacylglycerol, in pharmaceutical compositions and growth media comprising LL-37. | 2011-12-01 |
20110293708 | PROCESS FOR PREPARING PURIFIED NUCLEIC ACID AND THE USE THEREOF - The invention relates to a nucleic acid preparation with a content of below 1% protein, preferably below 0.1% protein, free of ethidium bromide, phenol, cesium chloride and detergents based on octyl phenol poly(ethylene glycol ether) | 2011-12-01 |
20110293709 | PEPTIDE TYROSINASE INHIBITORS AND USES THEREOF - Disclosed are peptides which inhibit the enzymatic activity of tyrosinase as well as formulations and methods for their use in the reduction of skin pigmentation, and methods of administering the inhibitory peptides in a topical formulation. Methods of skin treatment are also provided, the methods further including use of a peptide characterized by the amino acid sequence SFLLRN (SEQ ID NO: 1). | 2011-12-01 |
20110293710 | Immunomodulatory properties of lactobacillus strains - A specific method is provided of improving immunomodulatory properties of | 2011-12-01 |
20110293711 | Utilization of Dialkylfumarates - The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines. | 2011-12-01 |
20110293712 | COAXIALLY ENCAPSULATED CELL SUSPENSIONS AND MICROTISSUES - The present invention provides for the coaxial encapsulation of a plurality of cells in a single elongated compartment. By this encapsulation, the cells are protected by at least one layer of separation material and kept in close contact, which leads to a better vitality of the encapsulated cells and consequently results in higher chances to form microtissue. Methods and devices for the production of such encapsulated cell compartments are disclosed as well as medical uses of such compartments in cell, tissue therapy and tissue engineering. | 2011-12-01 |
20110293713 | PHARMACEUTICAL FORMULATIONS COMPRISING NSAID AND PROTON PUMP INHIBITOR DRUGS - Aspects of the present application relate to pharmaceutical formulations comprising a nonsteroidal anti-inflammatory drug, together with a proton pump inhibitor drug, to reduce the incidence of gastrointestinal complications associated with chronic therapy with a nonsteroidal anti-inflammatory drug. Specific aspects of the application relate to fixed dose combinations comprising aspirin, or a derivative thereof, and omeprazole or esomeprazole, or pharmaceutically acceptable salts, solvates, or hydrates thereof. | 2011-12-01 |
20110293714 | PHARMACEUTICAL COMPOSITIONS SUITABLE FOR ORAL ADMINISTRATION OF DERIVATIZED INSULIN PEPTIDES - The invention is related to a water-free liquid or semisolid pharmaceutical composition comprising a derivatized insulin peptide, at least one polar organic solvent and at least one lipophilic component and a method of treatment using such. | 2011-12-01 |
20110293715 | Pharmaceutical Formulation and Process for Its Preparation - The present invention relates to a multiparticulate tablet with improved gastro-protection comprising at least a pharmaceutically active substance in the form of enteric coated particles, and a mixture of tableting excipients, wherein the said mixture of excipients comprising xylitol and/or maltitol, each in a directly compressible form, a disintegrating agent, a lubricant and at least one other diluent and the ratio of a) the xylitol and/or the maltitol to b) the other diluent(s) is less than 5/95 (weight/weight) and the result of the “test of integrity of the film” is greater than 95%, preferably greater than 97% and more preferably still greater than 99% and the result of the “release test” is greater than 90%, preferably greater than 95%. According to one embodiment of the invention, the active substance is omeprazole or esomeprazole. According to another embodiment the tablet is a disintegratable tablet, which disintegrate in the mouth with or without chewing. The invention also comprises a process for preparing the claim tablet and its use in medicine. | 2011-12-01 |
20110293716 | PHARMACEUTICAL FORMULATION CONTAINING IBUPROFEN AND CODEINE - The invention consists of a new formulation of ibuprofen and codeine in the form of a tablet, which comprises L-leucine in a concentration ranging between 4%-15% as a lubricant, in order to prevent the formulation mixture from adhering to the punches and to other elements of the compression machine during the compression process. The new formulation additionally comprises talc (0.5%-5.0%) and silicified microcrystalline cellulose (30%-80%). The formulation is preferably arranged in the form of a core that comprises the active principles and, amongst others, the L-leucine, part of the talc and the silicified microcrystalline cellulose; this core is coated with a composition that contains a copolymer of methacrylic acid and ethyl acrylate. The tablets of the invention do not exhibit flaking problems, have an adequate hardness with a convenient attrition to allow for subsequent coating, offer disintegration values of less than 5 minutes, with dissolution values for both active principles in accordance with those specified for rapid-release tablets. | 2011-12-01 |
20110293717 | COMPACTED MOXIFLOXACIN - The invention relates to a process for the preparation of tablets containing moxifloxacin, comprising the steps of (i) providing moxifloxacin, pharmaceutically acceptable salts, solvates or hydrates thereof, optionally mixed with one or more pharmaceutical excipients; (ii) compacting it into a slug; (iii) granulating the slug; and (iv) compressing the resulting granules into tablets; and also tablets, granules and compacted material containing compacted moxifloxacin. | 2011-12-01 |
20110293718 | Compositions of R(+) and S(-) Pramipexole and Methods of Using the Same - Compositions of predetermined amounts of R(+) pramipexole and S(−) pramipexole and methods of using the same, including for the treatment and prevention of Parkinson's disease, are provided. | 2011-12-01 |
20110293719 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE - Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid. | 2011-12-01 |
20110293720 | PROGESTIN-CONTAINING DRUG DELIVERY SYSTEM - The present invention relates to drug delivery compositions in the form of thin water-soluble films (wafers), which contain small particles that comprise at least one progestin and at least one protective agent. The protective agent provides effective taste-masking of the progestin due to limited release of the progestin in the mouth. The progestin is hence not absorbed via the buccal route, but rather via the enteral (per-oral) route. | 2011-12-01 |
20110293721 | PIROXICAM-CONTAINING MATRIX PATCHES AND METHODS FOR THE TOPICAL TREATMENT OF ACUTE AND CHRONIC PAIN AND INFLAMMATION THEREWITH - This invention relates to matrix patches for the topical (i.e., transdermal) delivery of piroxicam and methods for the treatment of acute and chronic pain and inflammation therewith, particularly pain and inflammation caused by sports injuries or other muscle aches or injuries requiring the application of analgesic and/or anti-inflammation medication, in this instance, piroxicam. | 2011-12-01 |
20110293722 | HYDROGEL SPONGES, METHODS OF PRODUCING THEM AND USES THEREOF - A macroporous hydrogel sponge is provided selected from: (i) a synthetic polymer hydrogel sponge, and (ii) a synthetic polymer-polypeptide conjugate hydrogel sponge, the macroporous hydrogel sponge being at least 20% porous and having a pore diameter of 50-1000 μm, wherein said synthetic polymer is crosslinked to an extent determined by effecting the crosslinkig of the synthetic polymer or synthetic polymer-polypeptide conjugate in the presence of at least about 30% by weight crosslinking agent. | 2011-12-01 |
20110293723 | SYNTHETIC NANOCARRIER COMBINATION VACCINES - Disclosed are dosage forms and related methods, that include a first population of synthetic nanocarriers that have one or more first antigens coupled to them, one or more second antigens that are not coupled to the synthetic nanocarriers, and a pharmaceutically acceptable excipient. | 2011-12-01 |
20110293724 | Enzyme Treatment of Foodstuffs for Celiac Sprue - Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten. | 2011-12-01 |
20110293725 | CHIMERIC THERAPEUTICS, COMPOSITIONS, AND METHODS FOR USING SAME - Chimeric therapeutics are disclosed that include a modified viral core protein and a nucleic acid bound to the modified viral core protein. The nucleic acid may be substantially homologous to a specific gene target. In some embodiments, the nucleic acid bound to the modified viral core protein is substantially non-immunogenic. Also disclosed are particles and compositions that include disclosec chimeric therapeutics. | 2011-12-01 |
20110293726 | CHIMERIC THERAPEUTICS, COMPOSITIONS, AND METHODS FOR USING SAME - Chimeric therapeutics are disclosed that include a modified viral core protein and a nucleic acid bound to the modified viral core protein. The nucleic acid may be substantially homologous to a specific gene target. In some embodiments, the nucleic acid bound to the modified viral core protein is substantially non-immunogenic. Also disclosed are particles and compositions that include disclosed chimeric therapeutics. | 2011-12-01 |
20110293727 | CHIMERIC THERAPEUTICS, COMPOSITIONS, AND METHODS FOR USING SAME - Chimeric therapeutics are disclosed that include a modified viral core protein and a nucleic acid bound to the modified viral core protein. The nucleic acid may be substantially homologous to a specific gene target. In some embodiments, the nucleic acid bound to the modified viral core protein is substantially non-immunogenic. Also disclosed are particles and compositions that include disclosec chimeric therapeutics. | 2011-12-01 |
20110293728 | PHOTOSENSITIZER-METAL NANOPARTICLE COMPLEX AND COMPOSITION CONTAINING THE COMPLEX FOR PHOTODYNAMIC THERAPY OR DIAGNOSIS - Provided are a photosensitizer-metal nanoparticle complex and a composition for photodynamic therapy or diagnosis having the same. The complex includes a photosensitizer, a metal nanoparticle, and a backbone linking the photosensitizer with the metal nanoparticle. The backbone has a polypeptide substrate capable of being specifically degraded by a protease. When the complex is administered to a patient, fluorescence and production of reactive oxygen species from the conjugated photosensitizers are inhibited in normal tissues due to the resonance energy transfer between the photosensitizer and metal nanoparticles, but in tumor tissues, fluorescence and production of reactive oxygen species from the released photosensitizers are activated, thereby effectively destroying the tumor tissues. In addition, the selective fluorescence in the tumor tissues can further improve accuracy of tumor diagnosis using the protease-activatable photosensitizer-metal nanoparticle complex. | 2011-12-01 |
20110293729 | NOVEL COMPOSITION BASED ON GAMMA-HYDROXYBUTYRIC ACID - The present invention relates to a granule of gamma-hydroxybutyric acid or of one of its pharmaceutically acceptable salts, characterized in that it comprises a solid core on which the gamma-hydroxybutyric acid or one of its salts is supported. | 2011-12-01 |
20110293730 | Polylactide nanoparticles - A drug targeting system for administering a pharmacologically active substance to the central nervous system of a mammal across the animal's blood brain barrier. The drug targeting system comprises nanoparticles made of poly(DL-lactide) and/or poly(DL-lactide-co-glycolide), a pharmacologically active substance which is absorbed to, adsorbed to, and/or incorporated into the nanoparticles, and either contains TPGS or comprises a pluronic 188 surfactant coating deposited on the drug-loaded nanoparticles. | 2011-12-01 |
20110293731 | LOADING OF HYDROPHOBIC DRUGS INTO HYDROPHILIC POLYMER DELIVERY SYSTEMS - A process is described for loading hydrophilic polymer particles with a water-insoluble solvent-soluble drug. The particles are preferably embolic agents. The method provides particles having little or no drug at the surface and in a surface layer, whereby the burst effect is minimised. The drug is precipitated in the core of the particle, leading to extended release. The drug is, for instance, paclitaxel, rapamycin, dexamethasone or ibuprofen. | 2011-12-01 |
20110293732 | NANOPARTICLES MADE OF AMORPHOUS CELLULOSE - The present invention provides novel nanoscale cellulose particles and also a process for their production. The cellulose-based particles obtained have volume -averaged particle sizes of less than 300 nm. These nanoparticles are produced from amorphous cellulose or by amorphization of cellulose, optional subsequent hydrolysis and by input of energy into a water-containing medium after or during dispersion. | 2011-12-01 |
20110293733 | SELF-ASSEMBLING NANOPARTICLE DRUG DELIVERY SYSTEM - A self-assembling nanoparticle drug delivery system for the delivery of drugs including peptides, proteins, nucleic acids or synthetic chemical drugs is provided. The self-assembling nanoparticle drug delivery system described herein includes viral capsid proteins, such as Hepatitis B Virus core protein, encapsulating the drug, a lipid bi-layer envelope and targeting or facilitating molecules anchored in the lipid bilayer. A method for construction of the self-assembling nanoparticle drug delivery system is also provided. | 2011-12-01 |
20110293734 | NEW PLANT DERIVED SEED EXTRACT RICH IN ESSENTIALLY FATTY ACIDS DERIVED FROM SALVIA HISPANICA L. SEED: COMPOSITION OF MATTER, MANUFACTURING PROCESS AND USE | 2011-12-01 |
20110293735 | COMPOSITION OF PESTICIDE - A composition of pesticide is a composed of banana oil, pepper powder, urea, and milk powder. Banana oil is composed of ethyl acetate, n-butyl acetate, n-butanol, ketone, benzol, and xylene. Banana oil is diluted with water at a proper ratio. Pepper powder is added to banana oil to provide an excellent effect of pest killing. Urea is diluted with water at a proper ratio. Milk powder is added to urea to provide protection to plant leaves. With such a composition, a practical improvement of being environmentally conservative, toxicant free, and pollution free is realized. | 2011-12-01 |
20110293736 | FEED COMPOSITION COMPRISING A MINERAL COMPLEX AND METHODS OF USING THE MINERAL COMPLEX - The invention provides a mineral complex comprising about 40 wt. % to about 60 wt. % SiO | 2011-12-01 |
20110293737 | FEED COMPOSITION COMPRISING A MINERAL COMPLEX AND METHODS OF USING THE MINERAL COMPLEX - The invention provides a mineral complex comprising about 40 wt. % to about 60 wt. % SiO | 2011-12-01 |
20110293738 | FEED COMPOSITION COMPRISING A MINERAL COMPLEX AND METHODS OF USING THE MINERAL COMPLEX - The invention provides a mineral complex comprising about 40 wt. % to about 60 wt. % SiO | 2011-12-01 |
20110293739 | FEED COMPOSITION COMPRISING A MINERAL COMPLEX AND METHODS OF USING THE MINERAL COMPLEX - The invention provides a mineral complex comprising about 40 wt. % to about 60 wt. % SiO | 2011-12-01 |
20110293740 | TREATMENT SYSTEM AND METHOD FOR OSTEOPENIA AND OSTEOPOROSIS USING NON-SYNTHETIC BIO-AVAILABLE COMPOUNDS - A treatment system and method for osteopenia and osteoporosis using non-synthetic bio-available hormones, vitamins, minerals, and agents may be customized by varying the dosage and formulation of the components to maximize therapeutic effect, bioavailability, and patient comfort and compliance with their treatment method, the treatment system including a storage unit including a determined number of applications of hormones, minerals, and vitamins of appropriate dosages for treating the patient with osteopenia and osteoporosis. | 2011-12-01 |
20110293741 | ACIDIC OXIDANT-CONTAINING COMPOSITION HAVING ALUMINUM CORROSION-SUPPRESSING EFFECT AND USE THEREOF - The invention provides a liquid composition containing (a) an acidic oxidant, (b) nitric acid or a salt thereof, and (c) at least one carboxylic acid selected from the group consisting of monocarboxylic acids, dicarboxylic acids, and tricarboxylic acids, or a salt thereof. The liquid composition can be used to disinfect or sterilize a subject that includes a portion made of an aluminum-based metal. | 2011-12-01 |